Venn Life Sciences Holdings PLC Change of Adviser (9453T)

TIDMVENN

RNS Number : 9453T

Venn Life Sciences Holdings PLC

26 March 2019

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Change of Adviser

Venn Life Sciences, an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations, announces the appointment of Arden Partners plc as the Company's Nominated Adviser and Joint Broker with immediate effect, alongside its existing Joint Broker and ESM Adviser, Davy.

Enquiries:

Venn Life Sciences Holdings Plc Tel: +353 1 5499 341

Tony Richardson, Chief Executive Officer

Arden Partners (Nominated Advisor and Joint Broker) Tel: +44 (0)20 7614 5900

John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer

Davy (ESM Adviser and Joint Broker) Tel: +353 (0)1 679 6363

Fergal Meegan / Matthew de Vere White (Corporate Finance)

About Venn Life Sciences

Venn Life Sciences is an Integrated Drug Development Partner offering a unique combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations. Venn have dedicated operations in France, Germany, the Netherlands, the UK, Ireland with partners across Europe and the US.

Further information in relation to Venn Life Sciences www.vennlifesciences.com

Venn life Science: getintouch@vennlife.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

APPDELFLKXFLBBQ

(END) Dow Jones Newswires

March 26, 2019 03:01 ET (07:01 GMT)

Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024